Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hsf Pharmaceuticals SA operates within the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is being reviewed by 1 distinct examiner and is housed within 1 distinct art unit. The busiest examiner identified for the company is NGUYEN, QUANG, who is responsible for 1 pending office action. This single matter is processed through 1 distinct art unit, which is consistent with the Biotechnology & Pharmaceuticals technology area designation.
The portfolio's current activity is limited to the active workload managed by 1 distinct examiner. The busiest examiner pending 1 action covers the company's entire active docket. The data indicates a highly concentrated prosecution stage for Hsf Pharmaceuticals SA, with only the current matter requiring attention. Because there is only 1 distinct examiner and 1 distinct art unit, the company's current interactions with the patent office are centralized.
NGUYEN, QUANG represents the sole point of examiner contact for the pending matter currently in the system. This concentration ensures that the company's legal progress is tied to a specific technical and procedural path within the Biotechnology & Pharmaceuticals sector. Practitioners should observe that the 1 distinct art unit provides a singular framework for the evaluation of the company's current patent application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19086509 | REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFORE | NGUYEN, QUANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19086509 | REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFORE | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19086509 | REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFORE | NGUYEN, QUANG | 1631 | §103§112 | Final Rejection | — | Pending | Mar 21, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial